In 2005, the McGhan Style 153 double-lumen breast implant was removed from the market secondary to a higher rupture rate when contrasted with other implants in the Core Study group. The high rupture rate was attributed to the development of a posterior tear in the shell where the inner implant is bonded to the posterior wall of the device. The purpose of this study was to report the existing rupture rate and describe the apparent mechanism of failure in the Style 153 double-lumen breast implant. Methods: Ninety-seven patients (157 implants) who received the McGhan Style 153 double-lumen breast implant by the senior author were reviewed. Intraoperative observations and photographic images of ruptured implants were reviewed and characterized based on severity and location of implant rupture. Results: With a mean length of follow-up of greater than 6 years (82 months), the rupture rate was 19.1 percent per implant. Physical examination (60 percent) was the most common method of rupture detection. Ruptures tended to occur in the marginal aspect (63 percent) of the implant. Only three ruptures occurred secondary to a disruption of the inner bladder from the posterior portion of the implant.
S
ince the original introduction of saline and silicone gel breast implants for aesthetic and reconstructive breast surgery, numerous studies have been performed investigating the failure rates for these devices. [1] [2] [3] [4] [5] [6] Difficulty arises when attempting to interpret these reports for a particular device. Silicone gel implants have undergone a significant evolution over the past four decades, leading to a wide variety of devices. In general, studies lump these devices together when determining rupture rates, possibly obscuring increased failure rates of individual devices.
The McGhan Style 153 double-lumen breast implant represented an early generation of anatomically shaped silicone devices (Fig. 1 ). It contained a mildly cohesive gel with a Biocell textured surface. The implant was labeled as "internally stacked" secondary to an inner gel bladder that was overfilled, providing a stiffer feel and enhancing lower pole projection. This inner bladder was glued to the back of the outer silicone shell. Its indications for implantation encompassed all aspects of breast surgery, including: augmentation, reconstruction, and revision.
Secondary to the intense scrutiny by the U.S. Food and Drug Administration with regard to the premarket approval applications for silicone breast implants, large studies investigating failure rates of currently available devices have been generated. [5] [6] [7] In 2005, the McGhan Style 153 double-lumen breast implant was removed from the market secondary to 3-year follow-up data from the Core Study showing an elevated rupture rate that contrasted sharply with a 0.9 percent rupture rate for other round implants in that study group. 8 Before its removal, Inamed's application for approval of all their silicone devices was denied by the Food and Drug Administration secondary to an elevated failure rate. With exclusion of the McGhan Style 153 double-lumen breast implant from the Core Study group, however, the overall rupture rate decreased significantly and Inamed's silicone devices were approved.
As described in Inamed's formal presentation to the Food and Drug Administration, the high rupture rate was attributed to a design flaw that led to the development of a posterior tear in the shell where the inner implant is bonded to the posterior wall of the device. 8 To date, no data have been presented fully investigating the cause of failure for this device and its associated rupture rate. The purpose of this study is to review a single surgeon's experience with the 153 double-lumen implant, with the goal being to report the existing rupture rate and describe the apparent mechanism of implant failure.
METHODS
Ninety-seven patients (157 implants) who received the McGhan Style 153 double-lumen breast implant by the senior author between June of 1998 and July of 2002 were reviewed. All patients were enrolled in either the Core or Adjunct Study group, which involved a detailed study protocol, including yearly follow-up and physical examination. A select group of patients were part of a separate magnetic resonance imaging cohort. Data were collected detailing patient demographics, reason for implantation, intraoperative technique, and postoperative complications. Patients with known implant rupture were identified and analyzed for risk factors. Intraoperative observations and photographic images of ruptured implants were reviewed and characterized based on severity and location of implant rupture. The average length of follow-up was 82 months.
Summary statistics were calculated for the data. Quantitative variables are expressed as mean Ϯ SEM, whereas nominal data are expressed as a percentage.
RESULTS
Sixty-one patients were enrolled in the Adjunct Study (62.9 percent) with the remainder participating in the CORE Study. The average age was 49 years old at the time of 153 implantation. Surgical/medical procedures involving the breast before implantation with the 153 are detailed in Table 1 . Those with a history of implant placement may have been secondary to either a primary augmentation or reconstruction. Primary breast reconstruction was the principal reason for implantation in 60.8 percent of patients, followed by secondary reconstruction (32 percent), primary augmentation (3.1 percent), and secondary aesthetic surgery (3.1 percent). A majority of patients underwent bilateral procedures (61.9 percent). Implant placement following tissue expansion for primary breast reconstruction was the most common procedure performed at the time of implantation ( Table 2 ). The McGhan Style 153 double-lumen breast implants were available in five volumes (360, 450, 540, 630, and 720 cc) with the 450-cc implant being the most frequently implanted device (n ϭ 59, 37.6 percent). Drains were placed in 69.4 percent of the cases (n ϭ 109) with a dilute Betadine solution (n ϭ 120, 76.4 percent) or an antibiotic solution (n ϭ 30, 19.1 percent) being used to irrigate the pocket before implant placement.
Postoperative complications are detailed in Table 3 . Implant rupture was the most frequent complication (19.1 percent), followed by capsular contracture (Baker grade III, IV) and infection/ cellulitis. All infections were treated successfully with antibiotics, and there were no episodes of flap failure in the reconstructive cohort. Postimplantation surgical interventions included capsulectomy (n ϭ 32, 20.4 percent); nipple-areola complex revision (n ϭ 7, 4.5 percent); and capsulotomy and inframammary fold revision (both n ϭ 3, 1.9 percent).
Physical examination was the most common method of detecting implant rupture, followed by magnetic resonance imaging, operative exploration (i.e., at the time of capsulectomy for capsular contracture), and computed tomography (Table 4) . Findings on magnetic resonance imaging indicative of rupture include the "linguini sign," as well as the presence of free gel outside the implant (Fig. 2) . Examination findings indicative of a rupture included change in breast texture (n ϭ 5), breast shape (n ϭ 5), breast volume (n ϭ 2), and underlying seroma (n ϭ 2). The mean time until detection and confirmation of rupture was 70 months.
Primary reconstruction was the reason for implantation in 63 percent of ruptured implants. Ruptures were classified based on severity of rupture and condition of the elastomer shell at the time of explantation. Marginal tears occurred in 63 percent (n ϭ 19) of ruptures, whereas 17 percent (n ϭ 5) occurred centrally (Figs. 3 through  5 ). Six implants (20 percent) were indeterminate secondary to the severity of rupture. Table 5 further classifies ruptures based on location. Only three ruptures occurred secondary to disruption of the inner bladder from the posterior portion of the implant (Fig. 6) . The shape of most implants (70 percent) was maintained or only partially affected, whereas the remainder suffered complete loss of integrity. No clinically significant risk factors were identified.
DISCUSSION
Since Cronin and Gerow's introduction of silicone gel implants in 1962, silicone gel breast implants have undergone a significant evolution. Over the past 40 years, shell thickness, gel viscosity, surface texturing, and manufacturing techniques have all changed, culminating with the current so-called "fifth generation" cohesive silicone gel and form stable devices. Dual-chambered devices served as an extension of the early round saline and silicone implants. The outer silicone gel implant with an inner adjustable saline bladder connected to a fill device provided the surgeon with the capability of on the table size adjustments in aesthetic breast surgery versus serving as both an implant and tissue expander for reconstructive breast surgery. These devices differ from the McGhan Style 153 double-lumen implant. With the advent of the Biocell textured surface and subsequent increased stability of the implant initial application was denied secondary to the request for long-term safety data, which in turn, prompted the continuation of Core and Adjunct Studies. In April of 2005, Inamed Corporation went before the Food and Drug Administration with completed 3-year study data. Their application, however, was again rejected secondary to an overall high rupture rate. When the data were reevaluated, it was determined that the data were skewed secondary to the high rupture rate associated with the Style 153 implant, which was subsequently removed from the study group, eventually leading to approval of Inamed's silicone gel implants. The 153 double-lumen breast implant was never made available to the public and was available only to Core and Adjunct Study investigators.
To date, no raw data have been presented as to the true rupture rate of the Style 153 implant. Inamed's presentation to the Food and Drug Ad- ministration reviewed 442 explanted devices, of which 135 were ruptured and available for analysis. 8 Of those implants, 43 of 135 were ruptured 153's that resulted from posterior disruption of the implant where the inner lumen is bonded to the posterior wall. Interestingly, they presented 63 implants that were ruptured secondary to surgical damage and only one secondary to a fold flaw. Of these, which implants were 153's is unknown. Initially, plans were made to modify the 153 by reinforcing Volume 127, Number 1 • 153 Double-Lumen Breast Implant the posterior patch; however, at the recommendation of the Food and Drug Administration, the implant was subsequently removed from production.
Increased transparency is needed to truly determine the mechanism and incidence of failure for the 153. Based on a single surgeon's experience, a rupture rate of 19.1 percent at a minimum of 7 years and maximum of 11 years was identified. This number will only rise as the age of these devices increases. Despite what was previously thought, our review refutes the argument that these devices failed secondary to weakness in the posterior patch of the implant. A majority of ruptures occurred in the peripheral aspects of the implant and were likely secondary to fold flaws that led to failure of the implant shell. These flaws create sharply demarcated folds that weaken over time, leading to implant failure. Furthermore, this mechanism raises concern regarding the role that capsular contracture may play in implant failure. As the implant is deformed in a contracted pocket, inevitably folds are created in the surface of the implant, which ultimately may lead to implant failure.
CONCLUSIONS
This review serves as the first documented failure rate of the McGhan Style 153 doublelumen breast implant. The high failure rate is likely secondary to upper-pole fold flaws versus development of a posterior tear in the shell where the inner implant is bonded to the posterior wall of the device. Based on these results, it is recommended that patients with implanted 153's undergo continued postoperative screen- 
